One of the most appealing aspects of this company, since its inception in 2013, is its track record of avoiding reverse stock splits (r/s). Considering that this is a biotech stock operating in the early stages of development, it is common for such companies to rely on share dilution for working capital to sustain their operations. Many triple-zero stocks dilute hundreds of millions of shares on a weekly or even daily basis. However, this company has managed to maintain a relatively low outstanding share count of only 422 million over a span of ten years, which is exceptionally rare. This demonstrated restraint in share dilution speaks volumes about the company's trustworthiness and its commitment to its shareholders.
Currently, my focus is primarily on their pending spin-off. If they successfully secure a sponsor for this endeavor, it has the potential to be an extraordinary opportunity that could lead to an incredible ride for investors.
Market Data 
Markets 
